Kornimate/medical-research-clean huggingface dataset:
functional characteristic properties of skeletal muscle tissue assessed by p31 spectroscopy in young and older adults

Conditions: Sarcopenia

Summary: p31 nuclear magnetic resonance (rmn) spectroscopy (srm p31) has currently being poorly used in the field of sarcopenia. the aim of the camus study is to investigate the feasibility a protocol of srm p31 at rest, during and after a standardized physical task. the secondary objective is to compare the metabolism of tyhe skeletal muscle tissue assessed by srm p31 in young and older individuals. a pilot study, cross-sectional study will be conducted. ten healthy sedentary 70+ years males and 10 sedentary 25 to 30 years old male will be included. level of physical activity, physical performances, will be assessed at baseline. rmn (t1; tractography and srm p31) will be performed. srm p31 will be performed at rest, during and after an exhausting muscle task at 70% 1-rm. feasibility will be judged on the rate of valuable variables recorded (\>90%) inorganic phosphate (ip), phosphocreatine (pcr) and isoform of adenosine triphosphate (atp : alfa, beta, gamma).


Eligibility criteria:
inclusion criteria: * old group : 70+ years males * young group : 25 to 30 years males * sedentary males in the 2 groups * informed consent exclusion criteria: * contraindication to perform a rmn

Keywords: sarcopenia muscle strength srm p31 phosphocreatine
clinical study of extra-corporal life support in cardiogenic shock complicating acute myocardial infarction

Conditions: Cardiogenic Shock

Summary: this study compares standard treatment plus extra-corporal life support (ecls) versus standard treatment alone in patients with cardiogenic shock due to myocardial infarction.

cardiogenic shock is a serious complication of a myocardial infarction. despite optimal treatment the mortality in patients with cardiogenic shock still exceeds 50% and surviving patients mostly suffer from severe heart failure due to an impaired cardiac function. this study compares standard treatment plus extra-corporal life support (ecls) versus standard treatment alone in patients with cardiogenic shock due to myocardial infarction. the main study hypothesis is to explore if additional treatment with ecls preserves cardiac function (left ventricular ejection fraction) in patients with cardiogenic shock complicating acute myocardial infarction.

Eligibility criteria:
inclusion criteria: cardiogenic shock complicating acute myocardial (stemi or nstemi) with * intended revascularization (pci or cabg) * systolic blood pressure \ 30 min or inotropes required to maintain pressure \> 90 mmhg during systole * signs of left heart insufficiency and pulmonary congestion * signs of impaired organ perfusion with at least one of the following: * altered mental status * cold, clammy skin * urine output \<30 ml/h * serum lactate \>2mmol/l * informed consent exclusion criteria: * resuscitation \> 60 minutes, ischemia \> 10 minutes * no intrinsic heart action * cerebral deficit with fixed dilated pupils * mechanical infarction complication * onset of shock \> 12 h * severe peripheral artery disease * aortic regurgitation \> ii.° * age \> 80 years * shock of other cause * other severe concomitant disease * participation in another trial
an examination of cognitive fatigue using functional neuroimaging

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the purpose of this research study is to investigate the effectiveness of ms disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (rrms). cognitive fatigue is the kind of fatigue that occurs after intense mental concentration as after a session of problem solving.

the researchers aim is to investigate the effects of disease modifying treatments on cognitive fatigue and on specific brain areas that have been shown to underlie cognitive fatigue in individuals with multiple sclerosis (ms). the researchers will investigate the effects on the cognitive fatigue that develops during the performance of a demanding task, and also on how cognitive fatigue changes as a function of duration of treatment.

Eligibility criteria:
inclusion criteria: * age between 18-64. * relapsing remitting multiple sclerosis * been newly prescribed a new disease modifying medication for ms (either zeposia or other high dose oral efficacy medication) * or healthy volunteer who can speak english fluently. exclusion criteria: * history of head injury, stroke, seizures, or any other significant neurological event other than ms * flare up of ms symptoms within the past month. * history of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of major depressive disorder. * pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments. * left handed. * not able to have an mri
postoperative troponin in children with congenital heart disease

Conditions: Congenital Heart Disease

Summary: the aim of the study is to evaluate the value of postoperative troponin in the prediction of mid term and long term mortality and morbidity in children with congenital heart disease undergoing cardiac surgery.


Eligibility criteria:
inclusion criteria: * all children with congenital heart disease between 0-10 years admitted for elective or emergency corrective or palliative cardiac surgery exclusion criteria: * parental refusal * children older than 10 years
endophthalmitis cultures

Conditions: Endophthalmitis

Summary: the intent of this surveillance study will be to obtain written permission from patients with bacterial endophthalmitis in order to compare sterilization rates of their cultured bacterial isolates to standard therapy (vancomycin and ceftazidime) versus combination therapy with vancomycin, ceftazidime, and moxifloxacin. research hypothesis: 1. cultured bacterial isolates will demonstrate faster in vitro sterilization rates with combination treatment (vancomycin, ceftazidime, and moxifloxacin) compared to "standard therapy" with vancomycin and ceftazidime. 2. longitudinal analysis of resistance patterns of cultured isolates will show increasing rates of multi-antibiotic resistance.

adult patients over 18 years of age presenting with endophthalmitis and able to sign consent.

Eligibility criteria:
inclusion criteria: * all adult patients age 18 or greater presenting with bacterial endophthalmitis to the vanderbilt eye institute and who grow positive cultures exclusion criteria: * patients \< 18 years of age or those patients without positive cultures
predictors of mortality among ventilator associated pneumonia patients

Conditions: Pneumonia

Summary: in this context, this study aims to explore the risk factors for mortality from vap in respiratory icu.

pneumonia is the most common infection treated within icus and carries significant mortality risk . ventilator-associated pneumonia (vap) is a specific form of nosocomial pneumonia occurring in patients greater than 48 hours after intubation and the initiation of mechanical ventilation . vap is considered a leading cause of morbidity and mortality among intensive care unit infections. despite various preventive measures, the incidence of vap remains high . in studies, vap-related mortality is 14-70% . it is contemplated that there are independent risk factors, increasing vap-related mortality . however, the question of which factors are associated with early or late mortality in patients with vap diagnosis, remains unanswered. early identification and understanding of the etiology of vap in the icu is essential to prevent mortality and morbidity.

Eligibility criteria:
inclusion criteria:this study will enroll: 1. adult participants over 18 years old who had undergone mechanical ventilation for longer than 48 hours. 2. only the first episode of vap for each patient will be included. exclusion criteria: 1. patients who are less than 18 years old. 2. pneumonia diagnosed before mechanical ventilation.
mother and infant study cohort (misc)-

Conditions: Adiposity, Breast Feeding

Summary: this study aims to explore breastfeeding and complementary feeding practices of mothers in the united arab emirates (uae) and its relation to the early life determinants of obesity and non-communicable diseases (ncds). this research study will follow a prospective cohort approach. two hundred and fifty mother-infant pairs will be followed for 18 months. the hypothesis of this research study is that exclusive breastfeeding of the infant will provide potential protective effect against cardiometabolic risk factors. this study will also hypothesize that mothers who exclusively breastfeed their newborns would experience greater postpartum weight and body fat loss than mothers who are not breastfeeding.

united arab emirates(uae) is facing two critical situations: high incidence of obesity and chronic diseases and suboptimal infant feeding practices as reported by the ministry of health in the uae. so early identification of preventive markers of cardiometabolic risk factors in breast milk is important for developing early intervention strategies to optimize health care for individuals and communities especially in countries suffering from high rates of obesity and chronic diseases such as the uae. the purpose of this study is to prospectively follow up with the mothers and their infants (from 0-18months of infants age). it will explore breastfeeding and complementary feeding practices of mothers in uae and its relation to the early life determinants of obesity and non-communicable diseases (ncds). it will examine the components of human milk which might offer a protective benefit against obesity and its health consequences in infancy. it will also evaluate the feeding practices of the mothers and her nutritional status and relates it to their infants' growth and development. it is expected that this research study will fill an important knowledge gap in the understanding of the feeding practices of mothers and its relation to early-life determinants of obesity and other chronic diseases in the uae.

Eligibility criteria:
inclusion criteria: * pregnant women: * emirate nationality or arab expatriate * age: 19-40 years * singleton pregnancy * within the third trimester of pregnancy (27-42 weeks of gestation) * free of chronic diseases (diabetes, hypertension, kidney disease, cancer, or other chronic diseases), autoimmune disorders, or infections with the human immunodeficiency virus, or hepatitis in preconception exclusion criteria: * multiple pregnancies (pregnant with two or more fetuses) * high-risk pregnancy or pre-eclampsia * history of chronic diseases * preterm (\ 42 weeks of gestation) infants * congenital diseases or any health condition that could deter breastfeeding

Keywords: cohort noncommunicable diseases pregnancy infant cognition united arab emirates gestational diabetes
arsenic trioxide in treating patients with basal cell carcinoma

Conditions: Basal Cell Carcinoma of the Skin; Recurrent Skin Cancer

Summary: this pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing

primary objectives: i. to determine whether administration of arsenic trioxide (ato) to patients with basal cell carcinoma is associated with a reduction in gli messenger ribonucleic acid (mrna) and protein levels in tumor biopsy samples, when compared to baseline levels. secondary objectives: i. to determine whether there is evidence of tumor size reduction of ato against basal cell carcinoma in humans. outline: patients receive arsenic trioxide intravenously (iv) over 2 hours on days 1-5. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria * basal cell carcinoma (bcc) * ineligible for curative locoregional treatment and have either progressed on, did not tolerate, unwilling to try or ineligible for investigational smoothened antagonist such as vismodegib (gdc 0449), xl 139 (bms 833923), ipi- 926, lde225 and pf-04449913 * life expectancy estimate \> 3 months * performance status eastern cooperative oncology group (ecog) 0-2 * absolute neutrophil count ≥ 1,500/mcl * platelets ≥ 100,000/mcl * total bilirubin within normal institutional limits * aspartate aminotransferase (ast) (serum glutamic oxaloacetic transaminase \[sgot\])/alanine aminotransferase (alt) (serum glutamate pyruvate transaminase \[sgpt\]) ≤ 2.5 x institutional upper limit of normal * creatinine within normal institutional limits * corrected qt interval (qtc) by 12 lead electrocardiogram (ekg) \< 450 msecs * serum potassium within normal limits * magnesium within normal limits * calcium within normal limits * ability to understand and the willingness to sign a written informed consent document * evaluable tumor and be potentially eligible for pre and post ato tumor biopsy * receiving potassium wasting diuretics or amphotericin, while not excluded, must be noted to have theoretically increased arrhythmia risks with ato exclusion criteria * concurrent use of other investigational agents * cardiac arrhythmias * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recurrent seizure history or psychiatric illness/social situations that would limit compliance with study requirements * pregnant or lactating
the role of electrocardiograms in risk stratification and analysis of the characteristics of st elevation in acute myocarditis: a 2-centre study

Conditions: Myocarditis

Summary: the purpose of the present study was to investigate ecg findings of patients with acute myocarditis, ecg findings associated with fulminant myocarditis, and the characteristics of st-elevation on admission.

acute myocarditis is a severe disease with high mortality rate and various dynamic changes visible on electrocardiograms (ecgs). the aim were to investigate ecg findings in acute myocarditis, ecg findings associated with fulminant myocarditis (fm), and the characteristics of st elevation at admission. a retrospective analysis of 1814 ecgs was conducted from 274 consecutive patients with acute myocarditis aged ≥13 years, who were hospitalized in two centres between august 2007 and november 2019. all ecg obtained during the hospital course were evaluated by 2 electrophysiologists. a chi-square test was used to evaluate and compare the abnormal ecg findings between the fm and non-fm groups, and multivariate logistic regression analysis was performed to further evaluate ecg findings associated with fm. the mann-whitney u test was used to compare the duration of cardiac symptoms before admission for st elevation at admission.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute myocarditis * complete data of ecg exclusion criteria : * incomplete data; * a history of congenital heart disease, cardiomyopathy or arrhythmias; * myocarditis not being the primary diagnosis for a particular admission; * absence of cardiac symptoms.
use of intorus to control anxiety before exams in students at the university of extremadura

Conditions: STUDENT; Anxiety Disorders

Summary: the goal of this clinical trial is to assess the possible efficacy of the intorus device as an element to reduce test anxiety in university students. the main question\[s\] it aims to answer are: can the intorus device be used as a tool to reduce anxiety? once informed, those participants who meet the inclusion/exclusion criteria and sign the informed consent to participate in the study will be randomly divided into two groups. the randomization procedure will be carried out using the oxmar (oxford minimization and randomization) software. all participants will be given the sociodemographic questionnaire, self-efficacy scale and anxiety questionnaire prior to the start of the study.

the population is made up of students of the degree in occupational therapy during the 2nd semester of the 2022-2023 academic year. the initial sample size will be approximately 70 participants. - process once informed, those participants who meet the inclusion/exclusion criteria and sign the informed consent to participate in the study will be randomly divided into two groups. the randomization procedure will be carried out using the oxford minimization and randomization software. all participants will be given the sociodemographic questionnaire, self-efficacy scale and anxiety questionnaire prior to the start of the study. the participants of the experimental group will carry out a weekly exercise session with intorus aimed at reducing anxiety in the period between march 1, 2023 and may 10, 2023. on the day of the final exam for the subject, all students will repeat the anxiety measurement questionnaire and the perceived self-efficacy scale minutes before the final exam for the subject. once the intervention period is over, a questionnaire will be passed to the professionals participating in the study to assess the usefulness of the device, the degree of satisfaction with it and the usefulness of the therapies applied.

Eligibility criteria:
inclusion criteria: * students of the degree in occupational therapy at the university of extremadura. * students who are going to study the degree in occupational therapy in person. exclusion criteria: * not meeting the inclusion criteria * not wanting to participate in the study

Keywords: students anxiety occupational therapy
optimization of infliximab withdrawal strategy for rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: this multicenter prospective clinical trial investigates the accuracy of ultrasound to predict relapse after discontinuation of infliximab and the efficacy/safety of readministration of infliximab in patients with rheumatoid arthritis in a low disease activity state.

the objective of this multicenter prospective clinical trial is to determine whether ultrasound predicts relapse after discontinuation of infliximab more accurately than does clinical index and to investigate the efficacy and safety of restarting infliximab after relapse in patients with rheumatoid arthritis in remission or low disease activity on infliximab treatment. infliximab is discontinued in all enrolled patients. patients are followed up for 48 weeks for monitoring relapse. if relapse occurs, patients receive readministration of infliximab and are further followed up for 24 weeks to determine the efficacy and safety of infliximab readministration. primary endpoint is the difference in area under curve (auc) of receiver operator characteristics (roc) analysis between total power doppler score and disease activity score (das) 28 at baseline to predict relapse within 48 weeks after discontinuation of infliximab.

Eligibility criteria:
inclusion criteria: 1. 18 years or older 2. ra patients who fulfill 2010 acr/eular classification criteria 3. patients who have been treated with infliximab (remicade) for 26 weeks or longer 4. das28 (crp) \< 3.2 at screening 5. patients who give written informed consent after receiving sufficient information - exclusion criteria: 1. receiving prednisolone \> 10 mg/day 2. receiving biological or molecular-target anti-rheumatic drug 3. alteration of the dose of corticosteroid or anti-rheumatic drug within 8 weeks prior to screening visit 4. alteration of the dose of non-steroid anti-inflammatory drug within 4 weeks prior to screening visit 5. history of infusion reaction to infliximab 6. current infection which requires treatment 7. current or previous demyelinating disorder 8. current congestive heart failure which requires treatment 9. breast-feeding or pregnant/possibly pregnant woman, or woman who does not agree to prevent conception during and 6 months after study period 10. patients whom investigator or co-investigator consider inappropriate for other reasons -
methotrexate alone vs combination with excimer light in nail psoriasis

Conditions: Nail Psoriasis

Summary: the aim of this study is to compare the efficacy of excimer laser in combination with intralesional mtx injection to intralesional mtx injection alone in treating nail psoriasis

psoriasis is a chronic inflammatory disease affecting the skin, nails, and joints. approximately 61% of psoriatic patients have nail involvement. this percentage can increase up to 90% in patients with psoriatic arthritis. clinically, nail disease has many presentations depending on the location of the inflammatory process in either the matrix, the nail bed, or the periungual tissue, which results in distinct injury patterns. nail psoriasis can lead to impairment in the quality of life and work function due to pain, discomfort, and poor esthetic aspect. treating nail involvement is important in improving the health outcomes and quality of life among patients with psoriasis. nail psoriasis is a clinical diagnosis generally made in the context of existing psoriatic skin lesions. the nail psoriasis severity index (napsi) has recently been reported as a possible reproducible, objective, and simple tool for clinical assessment of psoriatic nail disease. treatment of nail psoriasis is challenging because of the anatomical properties of the nail unit that act as a barrier to active drug delivery and the naturally slow growth rate of the nail plate, which often delays noticeable clinical responses by months. treatment options available for nail psoriasis include topical therapy, intralesional injections, and systemic and biologic agents. poor penetration of topical therapy into the nail and surrounding tissue, adverse effects and monitoring of systemic therapies, and patient adherence to therapy make the treatment of nail psoriasis a challenge. few publications have been recently concerned intralesional injection of methotrexate in nail psoriasis. this therapy was documented for the first time in 2011. intramatricial injection of methotrexate is an interesting intralesional therapy as it provides a higher concentration of the drug at the site of action, while avoiding the complications seen with triamcinolone acetonide (injection site atrophy, disappearance of the phalanx under injection, or tendon rupture) the use of excimer laser for the treatment of psoriasis was first documented in 1997. the excimer laser induces t-cell apoptosis characterized by breaks in dna strands as well as expression of mitochondrial proteins associated with cell death.

Eligibility criteria:
inclusion criteria: * patients with bilateral fingernail psoriasis will be recruited. the diagnosis will be based upon the clinical characteristics of nail psoriasis. * patients will be included after they have stopped any systemic therapy for at least 8 weeks. exclusion criteria: * pregnant or lactating woman * patients with history of photosensitivity or keloid formation.

Keywords: nail psoriasis chronic psoriasis methotrexate excimer laser